Acquisition positions Chiesi to expand patient access to approved treatments and advance efforts to develop new treatments for people living with rare diseases.
Collaboration will enable rapid advancement of a joint preclinical proof of concept program for type 1 diabetes
FDA’s NME approvals declined substantially in 2022, causing overall New Drug Application (NDA) approvals to drop
Lonza supports development and manufacturing of ABL Bio’s bispecific antibody candidate with a complete and integrated end-to-end solution
SCYNEXIS will receive an upfront payment of $90 million with future performance-based milestone payments and tiered royalties
EIP Pharma to initiate in 2Q 2023 a Phase 2b clinical study, funded in part by a $21 million grant from the National Institute of Aging
The award recognizes and supports promising female scientists working in mass spectrometry
Pfizer’s total cumulative revenue from Seagen therapies is expected to reach $36 billion by 2028, according to GlobalData, a leading data and analytics company.
According to IQVIA sales data for the 12-month period ending January 2023, the Compazine Tablets, 5 mg and 10 mg market achieved annual sales of approximately US $26.9 million
Subscribe To Our Newsletter & Stay Updated
